NewAmsterdam Pharma (NAMS) Accumulated Expenses (2022 - 2026)

NewAmsterdam Pharma has disclosed Accumulated Expenses across 5 years of filings, most recently posting $2.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.3 million, up 15.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 15.56% YoY), and the FY2025 annual result was $9.4 million, up 7.27% from the prior year.
• Accumulated Expenses came in at $2.3 million for Q1 2026 at NewAmsterdam Pharma, down from $9.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.4 million in Q4 2025 to a low of $1.1 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $3.4 million (2023), against an average of $4.1 million.
• Across the five-year window, Accumulated Expenses jumped 157.71% in 2024 and climbed 7.27% in 2025, its largest moves.
• NewAmsterdam Pharma's Accumulated Expenses stood at $2.0 million in 2022, then soared by 69.37% to $3.4 million in 2023, then soared by 157.71% to $8.7 million in 2024, then advanced by 7.27% to $9.4 million in 2025, then tumbled by 75.7% to $2.3 million in 2026.
• The last three Accumulated Expenses figures came in at $2.3 million (Q1 2026), $9.4 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.